[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alcohol-withdrawal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alcohol-withdrawal":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,69,93,120,145,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100563637","motivational-interviews-post-hospitalisation-on-maintaining-abstinence-for-1-year-aprs-le-sevrage-en-alcool-100563637",false,"NCT06618755","Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool","IMMANENCE - Intérêt d'un Suivi Sous Forme d'Entretiens Motivationnels spécifiques Post Hospitalisation Sur le Maintien de l'AbstiNENCE Durant l'année Suivant le Sevrage en Alcool","IMMANENCE","Inclusion Criteria:\n\n* With alcohol use disorders defined by at least 2 DSM-V criteria for at least 12 months).\n* Being treated for withdrawal in hospital.\n* With a goal of complete abstinence.\n* With a means of communication (telephone).\n\nExclusion Criteria:\n\n* Lack of understanding (written and spoken) of the French language.\n* Breach of HC withdrawal contract, following failure to comply with the rules of the addictology service and somatic complications of addiction.\n* Eviction from the department, discharge against medical advice during hospitalisation for withdrawal.\n* Proven cognitive problems compromising understanding of the implications of the study and the proposed follow-up. proposed follow-up.\n* Serious decompensated somatic pathology.\n* Non-membership or non-beneficiaries of a national health insurance scheme.\n* Person protected by law, under guardianship or curatorship.\n* Not having signed free and informed consent to participate in the research.\n* Simultaneous participation in another clinical trial.","ALL","18 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this clinical study is to evaluate the efficacy of reinforced inpatient aftercare versus usual care on the percentage of days of abstinence during the first year following withdrawal in adults with alcohol use disorders undergoing inpatient withdrawal. The hypothesis is that reinforced post-withdrawal follow-up, of the motivational interview type, during the first 4 months following hospitalisation, in addition to the usual care, would allow :\n\n* Increase the percentage of days of abstinence in the year following withdrawal.\n* Reduce the rate of relapse in the year following withdrawal.\n* An increase in the cumulative and maximum duration of abstinence, an increase in motivation to maintain the change initiated and a reduction in the use of other substances in the year following withdrawal.\n* A reduction in the impact of risk factors involved in the relapse process in the year following withdrawal.\n\nAll participants will have assessments to monitor their abstinence and consumption. In addition to their assessments, the experimental group will have motivational talks once every 15 days.",[27,28,29,30,31],"Alcohol Use Disorder","Addiction","Alcohol Withdrawal","Motivational Interviews","Relapse","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":36},"2024-12-18",{"date":40,"type":21},"2028-01-13",{"name":42,"class":43},"University Hospital, Montpellier","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100627101","comparison-of-the-effect-on-anxiety-of-combining-hypnosis-and-aromatherapy-through-olfactory-anchoring-versus-standard-care-in-patients-undergoing-alcohol-withdrawal-100627101","NCT07444255","Comparison of the Effect on Anxiety of Combining Hypnosis and Aromatherapy Through Olfactory Anchoring Versus Standard Care in Patients Undergoing Alcohol Withdrawal","Randomized Trial Comparing the Effect on Anxiety of Combining Hypnosis and Aromatherapy Through Olfactory Anchoring Versus Standard Care in Patients Undergoing Alcohol Withdrawal","ASHA","Inclusion Criteria:\n\n* Patients aged 18 or over\n* Patients hospitalized in an addiction unit for acute alcohol withdrawal and suffering from anxiety disorders\n* Patients affiliated with a social security health insurance scheme, beneficiaries or dependents\n* Patients who speak\u002Fread French, are able to understand the objectives and risks associated with the research, and can give dated and signed informed consent\n* Patients who adhere to complementary therapies\n* For women of childbearing age, patients for whom the beta HCG test (urine or blood, performed routinely) is negative and who are using effective contraception.\n\nExclusion Criteria:\n\n* Allergy(ies)\u002Fcontraindication(s) to essential oils selected for the project\n* Patients with psychosis or complex psychological trauma\n* Anosmia, hyposmia, or other olfactory disorders limiting the quality of smell\n* Asthma\n* Ear, nose and throat pathology(ies) contraindicating essential oils in olfaction\n* Skepticism regarding the effectiveness of hypnosis and aromatherapy\n* Patient under guardianship\u002Fcuratorship\n* Patients excluded from a previous or ongoing study\n* Patients in an emergency or life-threatening situation\n* Patients under legal guardianship\n* Patients who have already participated in this study\n* Pregnancy\n* Breastfeeding",{"count":54,"type":21},80,[24],"According to a meta-analysis published in 2019, hypnosis has demonstrated positive effects in the treatment of certain mental illnesses, particularly anxiety. This technique aims to put the subject into a particular state of consciousness conducive to therapeutic action. The safe place in hypnosis is the basis for anxiety relief work, the first step towards the use of hypnotic metaphors. Smell is an excellent way to stimulate the imagination in creating this safe place.\n\nAnchoring allows the effects of a hypnosis session to be reactivated, enabling the subject to re-experience its benefits through tactile stimulation, a key word, or an image. The investigators use olfactory stimulation as a hypnotic anchor while also utilizing the anxiolytic properties of essential oils.\n\nWhile there are already studies on the use of hypnosis or aromatherapy in the treatment of patients who use psychotropic drugs, no study to date has focused on their combined use. The innovative aspect of this treatment lies in the prolongation and reinforcement of the effect of the hypnosis session through olfactory stimulation.\n\nThe literature shows that memories triggered by a smell have the ability to materialize physiologically in the areas of the brain that process spatial and temporal information. This is also a goal that hypnosis aspires to achieve.\n\nThe investigators hypothesize that the use of these two tools in formalized, time-limited nursing interviews can provide patients in the complex withdrawal unit with the means to reduce their anxiety in the short and medium term.",[29,58],"Anxiety","NOT_YET_RECRUITING","2026-03-04",{"date":62,"type":36},"2026-03-06",{"date":64,"type":21},"2026-03",{"date":66,"type":21},"2029-05",{"name":68,"class":43},"University Hospital, Strasbourg, France",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100423425","phase-2-prazosin-for-alcohol-use-disorder-with-withdrawal-symptoms-100423425","NCT04793685","Prazosin for Alcohol Use Disorder With Withdrawal Symptoms","Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms","Inclusion Criteria:\n\n* Alcohol Withdrawal (AW) scores of 3 or more on the CIWA-Ar at treatment entry OR 2 or more Alcohol Withdrawal Syndrome (AWS) symptoms and regular weekly heavy drinking at treatment entry;\n* Must meet current DSM-5 criteria for moderate to severe Alcohol Use Disorder (AUD) using SCID-I for DSM-5;\n* No health conditions that would impact trial participation as verified by screening and physical examination;\n* Able to read English and complete study evaluations\n* Able to provide informed written and verbal consent.\n\nExclusion Criteria:\n\n* Meet current criteria for moderate to severe substance use disorders from use of any another psychoactive substance, excluding nicotine, cocaine and cannabis;\n* Current use of illicit \u002Fnon-prescribed opioids more than 2X\u002Fmonth;\n* Regular use of anticonvulsants, sedatives\u002Fhypnotics, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), antiretroviral medications, tricyclic antidepressants, topiramate, baclofen, and regular weekly use of benzodiazepines, as defined by use of three or more times per week;\n* Prescribed use of antihypertensive medications that duplicate the mechanism of action at the alpha1 receptor as prazosin or are contraindicated, such as those medications that are also alpha1-adrenergic antagonists (i.e., doxazosin, tamsulosin, terazosin) or are beta-blockers (e.g., propranolol); Potential participants who are prescribed cardiovascular\u002Fantihypertensive medications will undergo clinical review by the study PIs and team. Individuals who are prescribed anti-hypertensives that do not duplicate the action of prazosin and are not contraindicated, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, and calcium channel blockers, may be allowed to participate after review from the study physician and principal investigators, with careful monitoring of these individuals' blood pressure at all in-person appointments.\n* Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania);\n* Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study;\n* Any psychotic disorder or current Axis I psychiatric disorders requiring specific attention, including need for psychiatric medications;\n* Hypotensive individuals with sitting blood pressure below 100\u002F50 mmHG;\n* Women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by pregnancy tests during initial medical evaluation, and assessed every two weeks during the course of the study).","70 Years",{"count":78,"type":21},150,[80],"PHASE2","This is a Phase 2 single site randomized clinical trial (RCT) to be supported by a new NIH-NIAAA grant, R01-AA029113-01, to assess the efficacy of Prazosin (16mg\u002Fday) versus Placebo over a 12 week treatment period, followed by a 1- and 3- month assessments post-treatment for individuals with Alcohol Use Disorder (AUD) and history of past or current evidence of alcohol withdrawal symptoms. If medical detoxification is required for any patient, patients would be enrolled after medical detoxification. for those not requiring detoxification, they will be enrolled directly without any requirement of alcohol abstinence. All patients will be provided behavioral counseling weekly with a trained counselor to support recovery during the trial. Primary outcome will be percent of any heavy drinking days and secondary drinking outcomes will be percent of subjects with no heavy drinking days (PSNHDD), avg drinks per drinking day and %of any drinking drinking days as well as additional secondary outcomes of craving, mood and anxiety problems.",[29],"2025-12-04",{"date":85,"type":36},"2025-12-11",{"date":87,"type":36},"2021-07-01",{"date":89,"type":21},"2027-06-30",{"name":91,"class":43},"Yale University",2,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":44},"100559120","phase-2-effects-of-ketone-supplementation-on-alcohol-withdrawal-and-brain-metabolism-in-alcohol-use-disorder-100559120","NCT06559995","Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder","KSAW","Inclusion Criteria:\n\n1. Able to communicate English and provide written informed consent\n2. Meets current DSM-5 criteria for moderate or severe AUD and seeking treatment for AUD\n3. Minimum 3-year history of heavy drinking (self-report).\n4. Presence of alcohol withdrawal (DSM-5)\n\nExclusion Criteria:\n\n1. Current DSM-5 diagnosis of a major psychiatric disorder (other than alcohol and nicotine use disorders) that would interfere with study procedures.\n2. Major medical problems that could impact brain function or the use of a Ketone supplement (e.g., epilepsy or diabetes) as determined by history and physical exam.\n3. Clinically significant laboratory findings that could affect brain function (e.g., HIV+)\n4. Head trauma with loss of consciousness for more than 30 minutes,\n5. Pregnant or breast-feeding\n6. BMI greater than 35\n7. Self-reported claustrophobia\n8. Contraindications to MRI (e.g., metal in the body that cannot be removed).\n9. Current, gastrointestinal (GI), liver or other clinically significant physical disease that may interfere with the intake of the Ketone Supplement based on medical history, and evaluation of the Study Physician.\n10. Current significant withdrawal from other substances, including benzodiazepines, opioids that require medication management for withdrawal and may interfere with study results\u002Fwithdrawal management plan.\n11. Judged by the principal investigator, Study Physician, or their designee to be an unsuitable candidate for the study.","65 Years",{"count":102,"type":21},30,[80,104],"PHASE3","The goal of this clinical trial is to learn the effects of ketone supplement compared to placebo on alcohol withdrawal symptoms during a 4 day alcohol withdrawal management treatment in adults with moderate to severe alcohol use disorder at the Hospital of the University of Pennsylvania, Cedar Detox Center.",[27,29,107],"Ketosis",[27,29,109,110],"ketosis","Ketone Supplement","2025-09-08",{"date":113,"type":36},"2025-09-15",{"date":115,"type":36},"2025-08-01",{"date":117,"type":21},"2027-12",{"name":119,"class":43},"University of Pennsylvania",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":44},"100575342","use-of-tan-in-alcohol-withdrawal-management-100575342","NCT06771037","Use of tAN® in Alcohol Withdrawal Management","The Use of Non-invasive Transcutaneous Auricular Neurostimulation (tAN®) in Alcohol Withdrawal Management","Inclusion Criteria:\n\n1. Ages 18 years old to 65 years old\n2. Entering an inpatient substance use treatment program for alcohol withdrawal management.\n3. Score a 27 or higher on the WHO-ASSIST V3.0\n4. Is proficient in English\n5. Score of a 4 or higher on the Prediction of Alcohol Withdrawal Severity Scale (PAWSS)\n6. Able to provide written informed consent.\n7. Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 or \\> 65\n2. Requires medical tapering from benzodiazepines or opioids.\n3. Has a history of epileptic seizures or seizures due to alcohol withdrawal.\n4. Has a cardiac pacemaker, cochlear prosthesis, neurostimulator or other device for which tAN® would be contraindicated.\n5. Has abnormal ear anatomy or an ear infection is present.\n6. Is pregnant.\n7. Has any serious medical disease or condition which, in the judgment of the Principal Investigator or his\u002Fher designee, would make study participation unsafe, or would make intervention compliance difficult.",{"count":128,"type":21},60,[24],"This research study is being conducted to learn if Transcutaneous Auricular Neurostimulation (tAN®) may be effective in treating alcohol withdrawal syndrome. Transcutaneous Auricular Neurostimulation (tAN®) works by delivering small electrical stimulations to the Vagus and Trigeminal nerves. This study will be conducted over the course of five days. Participants will be enrolled within 24 hours of entering treatment for alcohol withdrawal management. A total of 60 individuals will be enrolled and randomly assigned to either active (treatment with the device + treatment as usual) or sham (treatment as usual) group. Data will be collected on alcohol craving, use of comfort medications, sleep, and mood.",[29],[133,134,135],"Alcohol withdrawal","tAN","transcutaneous auricular neurostimulation","2025-04-16",{"date":138,"type":36},"2025-04-20",{"date":140,"type":21},"2025-04-21",{"date":142,"type":21},"2027-07-01",{"name":144,"class":43},"Erin Deneke",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":44},"100583589","bright-light-therapy-during-residential-alcohol-withdrawal-100583589","NCT06878287","Bright Light Therapy During Residential Alcohol Withdrawal","Bright Light Therapy During Residential Alcohol Withdrawal : a Double Blind Randomized Placebo Controlled Study","LUNA","Inclusion Criteria:\n\n* Patients must be aged from 18 to 65 years old and have a diagnosis of Alcohol Use Disorder\n* Patients must be intreated for alcohol withdrawal, for at least two weeks\n* Patients must report heavy drinking episodes in the past month\n* Patients must be able to understand medical information and consent to the treatment\n* Patients must be considering a goal of abstinence from alcohol\n\nExclusion Criteria:\n\n* Ophthalmic pathology (cataract, macular degeneration, glaucoma, retinitis pigmentosa) and diseases affecting the retina (retinopathy, diabetes, herpes, etc.)\n* Subjects who have already received light therapy in the last 6 months\n* Lactating of pregnant women\n* Psychiatric comorbidity requiring an intreatment, or risk of manic episode (subjects with depressive or anxious symptoms compatible with an out-treatment can be included)\n* Substance Use Disorder other than alcohol and\u002For tobacco\n* Severe cognitive impairment (MOCA \\\u003C 10)\n* Patients being under legal protection measure",{"count":154,"type":21},100,[24],"This is a randomized controlled trial assessing the effectiveness of light therapy versus placebo in patients undergoing alcohol withdrawal.",[27,29],"2025-03-11",{"date":160,"type":36},"2025-03-14",{"date":162,"type":36},"2022-05-31",{"date":164,"type":21},"2025-05-31",{"name":166,"class":43},"Centre Hospitalier St Anne",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":44},"100568002","validation-of-the-french-version-of-the-prediction-of-the-alcohol-withdrawal-severity-scale-pawss-100568002","NCT06675539","Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)","PAWSS-VF","Inclusion Criteria:\n\n* Male or female, aged 18 to 60 years\n* Subjects with DSM-5 criteria for alcohol use disorders (AUD)\n* Subjects hospitalized for scheduled withdrawal or patients developing alcohol withdrawal hospitalized for another reason.\n* Subjects who understand French\n* Subject affiliated to the French social security system\n* Subject having given their written consent to the study\n\nExclusion Criteria:\n\n* Subjects transferred from other hospitalization services for whom a withdrawal syndrome could have already been treated.\n* Subjects scheduled for discharge within 48 hours.\n* Subjects with known uncontrolled epilepsy.\n* Subjects unable to understand the questionnaire.\n* Subjects unable to give consent or not volunteering for the study.\n* Subjects under guardianship or curatorship.","60 Years",{"count":176,"type":21},545,"OBSERVATIONAL","The goal of this observational study is to validate the French version of the PAWSS scale in a population of patients with Alcohol Use Disorders. Prediction of Alcohol Withdrawal Severity Scale (PAWSS) has an excellent psychometric characteristics and predictive value of complicated alcohol withdrawal.\n\nThe main question it aims to answer is:\n\nAre the psychometric properties of the French version of the PAWSS scale comparable to those of the English version in a population of alcohol use disorders subjects?\n\nAUDs participants are included and followed for three days during their hospitalization, They will performed several scales and surveys (DSM-5 AUD criteria, AUDIT, French version of PAWSS and CIWA-AR).",[180,27,181,29],"Addiction, Substance","Alcohol Dependence",[27,183,184,185,186],"Scale","alcohol withdrawal","prediction","withdrawal syndrome","2025-02-24",{"date":189,"type":36},"2025-02-25",{"date":191,"type":36},"2024-11-11",{"date":193,"type":21},"2027-10",{"name":195,"class":43},"Etablissement Public de Santé Barthélemy Durand"]